Sleep Apnea

News of Note

A New Dopamine and Norepinephrine Reuptake Inhibitor for Excessive Sleepiness

Topics: Novel Medications | Pharmacology | Sleep Apnea | Sleep Disorders

Solriamfetol (Sunosi), a new dopamine and norepinephrine reuptake inhibitor (DNRI), has been approved by the FDA “to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.” The medication has never been studied in psychiatry, but is likely to have important psychiatric ­effects

Read More